Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of -5.87% and Operating profit at -136.50% over the last 5 years
2
With a fall in Net Sales of -8.42%, the company declared Very Negative results in Jun 25
3
Risky -
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,766 Million (Mid Cap)
NA (Loss Making)
NA
1.10%
0.04
-0.67%
0.91
Revenue and Profits:
Net Sales:
553 Million
(Quarterly Results - Jun 2025)
Net Profit:
11 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.77%
0%
-4.77%
6 Months
-4.85%
0%
-4.85%
1 Year
-19.96%
0%
-19.96%
2 Years
-28.81%
0%
-28.81%
3 Years
-40.34%
0%
-40.34%
4 Years
-61.43%
0%
-61.43%
5 Years
-75.2%
0%
-75.2%
Maccura Biotechnology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-5.87%
EBIT Growth (5y)
-136.50%
EBIT to Interest (avg)
15.01
Debt to EBITDA (avg)
0.18
Net Debt to Equity (avg)
0.02
Sales to Capital Employed (avg)
0.39
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
49.74%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
13.32%
ROE (avg)
11.25%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.91
EV to EBIT
-1218.25
EV to EBITDA
17.01
EV to Capital Employed
0.92
EV to Sales
2.61
PEG Ratio
NA
Dividend Yield
1.10%
ROCE (Latest)
-0.08%
ROE (Latest)
-0.67%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
553.00
504.60
9.59%
Operating Profit (PBDIT) excl Other Income
97.20
131.20
-25.91%
Interest
5.90
4.50
31.11%
Exceptional Items
-0.10
-11.50
99.13%
Consolidate Net Profit
11.10
25.50
-56.47%
Operating Profit Margin (Excl OI)
24.40%
94.00%
-6.96%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 9.59% vs -14.65% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -56.47% vs 115.52% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,522.90
2,868.60
-12.05%
Operating Profit (PBDIT) excl Other Income
584.20
635.90
-8.13%
Interest
23.00
34.50
-33.33%
Exceptional Items
-92.00
-16.60
-454.22%
Consolidate Net Profit
118.80
304.70
-61.01%
Operating Profit Margin (Excl OI)
97.80%
110.90%
-1.31%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -12.05% vs -19.73% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -61.01% vs -56.56% in Dec 2023
About Maccura Biotechnology Co., Ltd. 
Maccura Biotechnology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






